The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate

Evans, Christopher P.; Gajendran, Viswanathan; Tewari, Ashuthosh; Aslam, Khursheed; Juster, Richard P.; Gange, Steven; Eason, Anthony A.; Narayan, Perinchery

doi:10.1046/j.1464-410x.1996.00079.x

Cited by 7 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, after prostatectomy PSA levels should remain undetectable. While it remains a matter of controversy whether the PSA level prior to hormonal therapy has any prognostic significance [6][7][8], several preliminary studies have suggested that the percentage and velocity in decline of the PSA levels after hormonal therapy is associated with survival [9][10][11]. To evaluate the proportion of primary hormoneinsensitive, poor-prognosis prostate cancers and to estimate the prognostic significance of PSA decline after hormonal therapy, we retrospectively analysed the clinicopathological characteristics of 236 consecutive endocrinetreated prostate carcinomas diagnosed at Tampere University Hospital (TAUH).…”

Section: Introductionmentioning

confidence: 99%

PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer

et al. 1999

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer

et al. 1999

View full text Add to dashboard Cite

“…PSA has been used as a tumour marker for prostatic carcinoma for 10 years. Despite problems of sensitivity, the serum level of PSA is widely accepted to be the most Patients and methods useful tool for the early detection, evaluation and management of prostatic carcinoma [1][2][3]. More recent The cohort study comprised 218 patients with BPE aged 42-89 (mean 71) years and 43 patients with prostate studies have acknowledged that PSA exists in both a free and complexed form in the blood, and this may cancer aged 63-88 (mean 74) years, all of whom underwent elective TURP at Huddinge Hospital between make it possible to improve the diagnostic value of this blood test [4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Free and total prostate‐specific antigen serum concentrations do not help to detect prostate cancer in patients with urinary outlet obstruction

Trygg¹,

Pousette²,

Ekengren

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

Objectives To determine whether different molecular forms of prostate‐specific antigen (PSA) obtained before transurethral resection of the prostate (TURP) indicate the presence of prostate cancer. Patients and methods The free, total and free‐to‐total PSA levels were measured in 261 patients scheduled for TURP, 20 of whom had known prostate cancer. The tissue histology was compared with the PSA levels and the patients were followed for 5 years. Results Prostate cancer was detected in 23 of the patients (9%) who were thought to have benign disease. Normal ranges for the distribution of the PSA levels were established based on the patients with a benign histology, but these ranges did not detect most of the unknown cancers. The sensitivity of the total PSA test in detecting cancer was 38% and the specificity 90%. The discrimination was no better when considering the free fraction or the free‐to‐total PSA level. However, none of the 14 patients whose cancer was missed showed general progression of the disease during the 5‐year follow‐up and only one died from prostate cancer. In contrast, eight of the 20 patients with a known prostatic malignancy showed general progression, and six died from the disease. Conclusion PSA testing of patients with outlet obstruction often failed to detect prostate cancer, but the prognosis was moderately good in those patients in whom it was missed.

show abstract

“…This is obvious in Figs 2A‐C. We evaluated PSA and bone metastases, and reported that the proportional decrease in PSA level at 6 months is the best determinant of survival in patients with metastatic prostate cancer [1]; it correlated more closely than EOD. Furthermore, EOD has been shown in numerous studies to only correlate with survival when separating Grade 1 from Grade 2–4.…”

mentioning

confidence: 99%

Editorial comment

Evans¹

2003

BJU International

View full text Add to dashboard Cite

compared with those of the extent of disease (EOD) grades in bone lesions and serum prostate specific antigen (PSA) levels according to treatment response. RESULTSSerial values of EOD grades and %PABS decreased during treatment in 11 patients with a partial response and in 12 with progressive disease who had no bone metastasis progression. However, EOD grades and %PABS increased in the remaining 19 patients with progressive disease who had bone metastatic progression. Estimated survival curves showed that %PABS was a useful prognostic indicator, in that patients with a >25% decline in %PABS survived longer than those with a <25% decline after treatment ( P = 0.0207). CONCLUSIONSThe %PABS is a simple and reproducible estimate of the proportion of the skeleton involving tumours in patients with advanced prostate cancer, and serial measurements of %PABS can assist in monitoring the treatment response in patients with bone metastatic prostate cancer. KEYWORDS prostate neoplasms, bone metastasis, bone scintigraphy OBJECTIVETo assess the clinical usefulness of quantifying the extent of disease on bone scans in monitoring treatment response in patients with advanced prostate cancer, using computer-assisted image analysis. PATIENTS AND METHODSThe percentage of the positive area on the bone scan (%PABS) was quantified automatically using a personal computer with an image-analysis program. Serial measurements of %PABS in 42 patients with bone metastasis from prostate cancer followed for a mean (range) of 33 (4-72) months with hormonal therapy were

show abstract

The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate

Cited by 7 publications

References 4 publications

PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer

PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer

Free and total prostate‐specific antigen serum concentrations do not help to detect prostate cancer in patients with urinary outlet obstruction

Editorial comment

Contact Info

Product

Resources

About